A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MBX Biosciences
- Last updated on ClinicalTrials.gov
- June 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- MBX Biosciences Investigational Site · Doral, FL
Kentucky · 1
- MBX Biosciences Investigational Site · Lexington, KY
Missouri · 1
- MBX Biosciences Investigational Site · Kansas City, MO
Tennessee · 1
- MBX Biosciences Investigational Site · Knoxville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.